118 related articles for article (PubMed ID: 2125758)
21. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
22. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
23. [Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects].
Samama M; Verdy E; Conard J; Vahanian A; Michel P; Van Dreden P; Nguyen G; Horellou MH; Combrisson A; Acar J
Arch Mal Coeur Vaiss; 1986 Oct; 79(11):1618-24. PubMed ID: 3103572
[TBL] [Abstract][Full Text] [Related]
24. Effect of epsilon-aminocaproyl-S-benzyl-L-cysteine on the activity of plasminogen activators.
Bruzgo I; Midura-Nowaczek K; Kaczyńska J; Krajewska D
Acta Pol Pharm; 2009; 66(1):37-40. PubMed ID: 19226966
[TBL] [Abstract][Full Text] [Related]
25. Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate.
Carranza YE; Durand-Rougley C; Doctor V
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):483-7. PubMed ID: 18685430
[TBL] [Abstract][Full Text] [Related]
26. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
28. Recombinant tissue plasminogen activator: implications in therapy.
Topol EJ
Semin Hematol; 1989 Jul; 26(3 Suppl 3):25-31. PubMed ID: 2508227
[TBL] [Abstract][Full Text] [Related]
29. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
30. The susceptibility of plasma to activation of fibrinolysis.
Stief TW
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
[TBL] [Abstract][Full Text] [Related]
31. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
32. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
33. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
35. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
36. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
Bangert K; Thorsen S
Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
[TBL] [Abstract][Full Text] [Related]
37. Interaction of a plasminogen activator proteinase, LV-PA with human alpha2-macroglobulin.
Hermogenes AL; Richardson M; Magalhaes A; Yarleque A; Rodriguez E; Sanchez EF
Toxicon; 2006 Mar; 47(4):490-4. PubMed ID: 16458339
[TBL] [Abstract][Full Text] [Related]
38. Substitution of serine or threonine at position 473 of tissue-type plasminogen activator increases its stability in plasma.
Alibhai M; Chow AM; Paoni NF
Thromb Haemost; 1996 Jan; 75(1):107-12. PubMed ID: 8713788
[TBL] [Abstract][Full Text] [Related]
39. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
40. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
Aisina RB; Moukhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
